Crameri Reto
Professor, Swiss Institute of Allergy and Asthma Research (SIAF), Head Molecular Allergology Department, Obere Strasse 22, CH-7270 Davos, Switzerland.
Expert Rev Vaccines. 2007 Dec;6(6):991-9. doi: 10.1586/14760584.6.6.991.
Allergy, extrinsic asthma and atopic eczema derive from deregulated immune responses against innocuous antigens. The incidence of atopic diseases is actually affecting approximately 30% of the population in industrialized countries. Although much progress has been achieved in the development of efficient symptomatic treatments for allergic diseases, the only curative treatment remains allergen-specific immunotherapy. In contrast to classical vaccines, which elicit strong host immune responses after one or a few injections, allergen-specific immunotherapy might require a long treatment time of 3-5 years with up to 80 injections to confer some protection. The reality is that 'allergy vaccines' achieve beneficial effects through immunomodulation, which takes a long time to establish. The dream would be to develop highly efficient allergy vaccines able to cure the disease with a few injections.
过敏、外源性哮喘和特应性皮炎源于针对无害抗原的免疫反应失调。在工业化国家,特应性疾病的发病率实际上影响着约30%的人口。尽管在开发有效的过敏性疾病对症治疗方法方面已经取得了很大进展,但唯一的治愈性治疗方法仍然是变应原特异性免疫疗法。与经典疫苗不同,经典疫苗在注射一次或几次后会引发强烈的宿主免疫反应,而变应原特异性免疫疗法可能需要长达3至5年的长期治疗,注射多达80次才能提供一定的保护。现实情况是,“过敏疫苗”通过免疫调节发挥有益作用,而这需要很长时间才能建立起来。理想的情况是开发出高效的过敏疫苗,只需注射几次就能治愈疾病。